Plant ID: NPO21349
Plant Latin Name: Punica granatum
Taxonomy Genus: Punica
Taxonomy Family: Lythraceae
NCBI TaxonomyDB:
22663
Plant-of-the-World-Online:
n.a.
Antibacterial; Antidiarrhoeal; Antiviral; Astringent; Cardiac; Demulcent; Emmenagogue; Refrigerant; Stomachic; Vermifuge
Turkey; Madagascar; Italy; Turkmenistan; Rwanda; Swaziland; Argentina; Nigeria; Zimbabwe; Jordan; Thailand; Iraq; Tanzania; Philippines; Indonesia; United States; Angola; Mexico; Tunisia; South Africa; India; Malaysia; China; Greece; Sri Lanka; Kenya
GPR35; FFAR1; FFAR4; ADRA2B; | |
TSHR; NPSR1; | |
ALPL; TDP1; BLM; RECQL; MTOR; GLO1; HPGD; HSD17B1; AKR1B1; HSD17B2; HSD17B10; ALOX15; AKR1B10; ALOX12; NOX4; USP2; APEX1; POLB; | |
ACHE; | |
CDC25B; | |
TOP2A; | |
MET; CSNK2A1; AXL; FLT3; SRC; IGF1R; AURKB; TEK; INSR; CDK1; EGFR; PIM1; NUAK1; KDR; | |
CA12; CA14; CA7; CA4; CA2; | |
THRB; | |
NR1H4; | |
PPARA; | |
RORC; | |
ESR1; ESR2; | |
KDM4E; | |
TYR; | |
F10; F2; | |
MMP12; MMP2; MMP9; MMP1; | |
BACE1; | |
AHR; HIF1A; NFKB1; | |
FUT7; | |
SLC5A1; SLC5A2; SLC22A6; SLC5A4; SLCO1B3; SLCO1B1; | |
SMAD3; LMNA; FABP5; FABP4; PMP22; FABP3; GMNN; RAB9A; TUBB3; HSPA1A; | |
L3MBTL1; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | MTOR | Serine/threonine-protein kinase mTOR | P42345 | CHEMBL2842 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Nuclear hormone receptor subfamily 1 group A | THRB | Thyroid hormone receptor beta-1 | P10828 | CHEMBL1947 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
Serine protease | F10 | Coagulation factor X | P00742 | CHEMBL244 |
Serine protease | F2 | Thrombin | P00734 | CHEMBL204 |
SLC superfamily of solute carriers | SLC5A1 | Sodium/glucose cotransporter 1 | P13866 | CHEMBL4979 |
SLC superfamily of solute carriers | SLC5A2 | Sodium/glucose cotransporter 2 | P31639 | CHEMBL3884 |
SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
SLC superfamily of solute carriers | SLC5A4 | Low affinity sodium-glucose cotransporter | Q9NY91 | CHEMBL1770047 |
SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | PMP22 | Peripheral myelin protein 22 | Q01453 | CHEMBL1293298 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | GMNN | Geminin | O75496 | CHEMBL1293278 |
Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
Unclassified | TUBB3 | Tubulin beta-3 chain | Q13509 | CHEMBL2597 |
Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 4.782E-09 | 2.083E-06 | CA12, CA14, CA2, CA4, CA7 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.780E-08 | 6.154E-06 | BLM, CA12, CA2, CA4, CA7, ESR1, ESR2, GLO1, L3MBTL1, MMP1, MMP12, MMP2, MMP9, NR1H4, PPARA, RORC, SMAD3, THRB |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 2.773E-08 | 8.505E-06 | AXL, EGFR, F10, INSR, MET, MTOR, NOX4, SRC, TEK |
BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 4.876E-08 | 1.344E-05 | CYP19A1, F2, FFAR4, NFKB1, NR1H4, PPARA, SMAD3, TEK |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.959E-08 | 1.348E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, NOX4 |
BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 5.614E-08 | 1.438E-05 | ALPL, APEX1, BLM, CYP1A1, CYP1B1, EGFR, ESR1, FLT3, NFKB1, NOX4, RORC, SRC |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 7.896E-08 | 1.829E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 8.060E-08 | 1.848E-05 | AKR1B1, AKR1B10, ALOX12, ALOX15, APEX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, HPGD, HSD17B1, HSD17B10, HSD17B2, KDM4E, MTOR, NOX4, TYR |
BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 9.361E-08 | 2.101E-05 | AHR, ESR1, ESR2, NR1H4, PIM1, PPARA, RORC, SRC, THRB |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.576E-07 | 3.149E-05 | CA2, CA4, EGFR, HPGD, SLC22A6, SLCO1B1, SLCO1B3, TEK, TSHR |
MF | Unclassified; | GO:0004872; receptor activity | 2.425E-07 | 4.551E-05 | ADRA2B, AHR, AXL, EGFR, ESR1, ESR2, F2, FFAR1, FFAR4, FLT3, GPR35, HPGD, IGF1R, INSR, KDR, MET, NPSR1, NR1H4, PPARA, RORC, TEK, THRB, TSHR |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.561E-06 | 2.137E-04 | CA12, CA14, CA2, CA4, CA7 |
MF | GO:0005215; transporter activity | GO:0005412; glucose:sodium symporter activity | 1.748E-06 | 2.349E-04 | SLC5A1, SLC5A2, SLC5A4 |
MF | GO:0005488; binding | GO:0020037; heme binding | 1.791E-06 | 2.378E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, NOX4, SRC |
BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 1.987E-06 | 2.590E-04 | ESR1, ESR2, NR1H4, PPARA, RORC, SRC, THRB |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.167E-06 | 2.779E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 2.181E-06 | 2.779E-04 | EGFR, IGF1R, INSR, KDR, SRC |
MF | GO:0005488; binding | GO:0042562; hormone binding | 2.306E-06 | 2.902E-04 | ACHE, EGFR, HSD17B1, IGF1R, INSR, THRB |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.184E-06 | 3.852E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 3.348E-06 | 3.962E-04 | ADRA2B, AXL, BACE1, FFAR1, FFAR4, FLT3, GPR35, IGF1R, INSR, KDR, MET, NPSR1, SLC22A6, SLC5A1, SLC5A2, SLC5A4, SLCO1B1, SLCO1B3, TEK, TSHR |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 4.136E-06 | 4.816E-04 | AHR, AKR1B1, APEX1, AURKB, BLM, CDC25B, CDK1, CSNK2A1, ESR1, ESR2, FABP5, GMNN, HIF1A, HPGD, HSPA1A, L3MBTL1, LMNA, MTOR, NFKB1, NR1H4, NUAK1, PIM1, POLB, PPARA, RECQL, RORC, SMAD3, SRC, THRB, TOP2A, USP2 |
MF | GO:0005488; binding | GO:0005504; fatty acid binding | 6.224E-06 | 6.669E-04 | FABP3, FABP4, FABP5, FFAR4 |
MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 7.270E-06 | 7.502E-04 | EGFR, INSR, KDR |
BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 7.865E-06 | 7.924E-04 | CDK1, ESR1, ESR2, NR1H4, PPARA, RORC, THRB |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 7.865E-06 | 7.924E-04 | ALOX12, ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 8.050E-06 | 8.041E-04 | AKR1B1, APEX1, AXL, CDK1, CYP1B1 |
MF | GO:0005488; binding | GO:0042802; identical protein binding | 8.228E-06 | 8.144E-04 | ACHE, BLM, CSNK2A1, EGFR, ESR1, ESR2, FLT3, HPGD, IGF1R, KDR, L3MBTL1, MET, MMP9, MTOR, NFKB1, RAB9A, SLC22A6, SMAD3, TOP2A, TYR, USP2 |
BP | GO:0032501; multicellular organismal process | GO:0001503; ossification | 1.267E-05 | 1.169E-03 | ALOX15, ALPL, EGFR, MMP2, MMP9, TEK |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 1.254E-05 | 1.169E-03 | AHR, CSNK2A1, HIF1A, KDR |
BP | GO:0009987; cellular process | GO:0007169; transmembrane receptor protein tyrosine kinase signaling pathway | 1.460E-05 | 1.303E-03 | AXL, EGFR, FLT3, IGF1R, INSR, KDR, MET, MMP2, MMP9, SRC, TEK |
BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 1.606E-05 | 1.421E-03 | ADRA2B, INSR, MTOR, SRC |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 2.005E-05 | 1.680E-03 | APEX1, POLB |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 2.005E-05 | 1.680E-03 | ALOX12, ALOX15 |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 2.005E-05 | 1.680E-03 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 2.005E-05 | 1.680E-03 | ALOX12, ALOX15 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.026E-05 | 1.690E-03 | CA12, CA2, CA4, CA7 |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 2.371E-05 | 1.956E-03 | AXL, CDK1, CSNK2A1, EGFR, FLT3 |
BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 2.443E-05 | 1.999E-03 | CYP19A1, HSD17B1, HSD17B2 |
MF | GO:0005488; binding | GO:0005524; ATP binding | 2.497E-05 | 2.021E-03 | AURKB, AXL, BLM, CDK1, CSNK2A1, EGFR, FLT3, HSPA1A, IGF1R, INSR, KDR, MET, MTOR, NUAK1, PIM1, RECQL, SRC, TEK, TOP2A |
BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 2.527E-05 | 2.027E-03 | ALOX15, EGFR, MTOR, PPARA, SMAD3 |
BP | GO:0009987; cellular process | GO:0051495; positive regulation of cytoskeleton organization | 2.835E-05 | 2.220E-03 | ALOX15, HSPA1A, MET, MTOR, NOX4, SMAD3, TEK |
BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 3.026E-05 | 2.362E-03 | ALOX15, EGFR, FFAR4, KDR, NOX4, SRC, TEK |
BP | GO:0032502; developmental process | GO:0060065; uterus development | 3.099E-05 | 2.402E-03 | CYP19A1, ESR1, SRC |
BP | GO:0008152; metabolic process | GO:0045429; positive regulation of nitric oxide biosynthetic process | 3.423E-05 | 2.604E-03 | EGFR, INSR, MTOR, SMAD3 |
BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 3.548E-05 | 2.664E-03 | ALPL, AXL, CYP1A1, CYP1A2, HPGD, NFKB1, NR1H4, SRC |
BP | GO:0009987; cellular process | GO:0001961; positive regulation of cytokine-mediated signaling pathway | 4.143E-05 | 3.007E-03 | AXL, HIF1A, HSPA1A, MMP12 |
BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 4.315E-05 | 3.090E-03 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
MF | GO:0005488; binding | GO:0005496; steroid binding | 4.315E-05 | 3.090E-03 | ESR1, ESR2, HSD17B1, NR1H4, RORC |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 4.737E-05 | 3.338E-03 | ALOX12, ALOX15, HPGD |
BP | GO:0009987; cellular process | GO:0045931; positive regulation of mitotic cell cycle | 4.754E-05 | 3.339E-03 | APEX1, CDC25B, CDK1, CYP1A1, INSR, USP2 |
BP | GO:0008152; metabolic process | GO:0045893; positive regulation of transcription, DNA-templated | 4.932E-05 | 3.442E-03 | AHR, BLM, EGFR, ESR1, ESR2, HIF1A, INSR, MET, MMP12, MTOR, NFKB1, NR1H4, PPARA, RORC, SMAD3, SRC, THRB, TOP2A |
MF | Unclassified; | GO:0032403; protein complex binding | 5.403E-05 | 3.696E-03 | ACHE, APEX1, EGFR, FLT3, IGF1R, INSR, KDR, MMP12, MMP9, PPARA, SMAD3, SRC, TSHR |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 5.999E-05 | 3.908E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 5.999E-05 | 3.908E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 5.999E-05 | 3.908E-03 | ALOX12, ALOX15 |
MF | GO:0005488; binding | GO:0003690; double-stranded DNA binding | 8.162E-05 | 5.092E-03 | AHR, APEX1, EGFR, ESR1, ESR2, HIF1A, MTOR, NFKB1, NR1H4, PPARA, RORC, SMAD3, TDP1 |
BP | GO:0032502; developmental process | GO:0007568; aging | 8.288E-05 | 5.156E-03 | APEX1, AURKB, CDK1, CYP1A1, MTOR, NOX4, POLB |
MF | GO:0005488; binding | GO:0003682; chromatin binding | 8.432E-05 | 5.231E-03 | APEX1, CDK1, EGFR, ESR1, GMNN, L3MBTL1, NFKB1, SMAD3, THRB, TOP2A |
BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 9.226E-05 | 5.612E-03 | ACHE, EGFR, FFAR1, HIF1A, MMP12, NR1H4, SRC |
MF | GO:0005488; binding | GO:0001223; transcription coactivator binding | 9.519E-05 | 5.726E-03 | AHR, ESR1, PPARA |
BP | GO:0032501; multicellular organismal process | GO:0032922; circadian regulation of gene expression | 1.099E-04 | 6.449E-03 | AHR, PPARA, RORC, USP2 |
BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 1.099E-04 | 6.449E-03 | CDK1, EGFR, IGF1R, INSR |
BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 1.170E-04 | 6.776E-03 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
BP | GO:0050896; response to stimulus | GO:0009314; response to radiation | 1.185E-04 | 6.829E-03 | AURKB, BLM, EGFR, HIF1A, MTOR, NOX4, POLB, TYR, USP2 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.196E-04 | 6.837E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.196E-04 | 6.837E-03 | ESR1, ESR2 |
BP | Unclassified; | GO:0035428; hexose transmembrane transport | 1.277E-04 | 7.114E-03 | SLC5A1, SLC5A2, SLC5A4 |
BP | GO:0051179; localization | GO:1904659; glucose transmembrane transport | 1.277E-04 | 7.114E-03 | SLC5A1, SLC5A2, SLC5A4 |
BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 1.277E-04 | 7.114E-03 | HPGD, MMP2, MMP9 |
BP | GO:0009987; cellular process | GO:0030520; intracellular estrogen receptor signaling pathway | 1.277E-04 | 7.114E-03 | ESR1, ESR2, SRC |
BP | GO:0009987; cellular process | GO:1902905; positive regulation of supramolecular fiber organization | 1.312E-04 | 7.286E-03 | ALOX15, HSPA1A, MET, MTOR, NOX4, SMAD3 |
BP | GO:0008152; metabolic process | GO:0070988; demethylation | 1.446E-04 | 7.933E-03 | APEX1, CYP1A1, CYP1A2, KDM4E |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.464E-04 | 8.012E-03 | CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0005215; transporter activity | GO:0015347; sodium-independent organic anion transmembrane transporter activity | 1.668E-04 | 8.924E-03 | SLC22A6, SLCO1B1, SLCO1B3 |
BP | GO:0023052; signaling | GO:0023057; negative regulation of signaling | 1.873E-04 | 9.897E-03 | ACHE, ADRA2B, EGFR, ESR1, ESR2, GPR35, HIF1A, HSPA1A, IGF1R, LMNA, MET, MMP12, MMP9, NR1H4, SMAD3, SRC |
BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 1.889E-04 | 9.914E-03 | FABP3, FABP4, FABP5 |
BP | GO:0065007; biological regulation | GO:0043406; positive regulation of MAP kinase activity | 1.895E-04 | 9.918E-03 | ADRA2B, CDK1, EGFR, FLT3, INSR, NOX4, SRC |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.979E-09 | 3.225E-07 | HSD17B1, INSR, HSD17B2, CYP1A1, CYP1B1, CYP19A1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.886E-08 | 1.025E-06 | SRC, MMP2, KDR, HIF1A, ESR1, MMP9, MET, EGFR, MTOR, IGF1R |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 3.277E-08 | 1.335E-06 | SMAD3, CSNK2A1, SRC, INSR, MET, EGFR, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 2.484E-07 | 6.747E-06 | SRC, MMP2, ESR1, MMP9, EGFR, ESR2, HSPA1A |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 8.233E-09 | 6.710E-07 | CA12, CA2, CA4, CA7, CA14 |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.190E-06 | 2.155E-05 | SMAD3, FLT3, MMP1, MMP2, HIF1A, MET, MMP9, EGFR, NFKB1, MTOR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 3.260E-07 | 7.590E-06 | INSR, TEK, HIF1A, EGFR, NFKB1, MTOR, IGF1R |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.921E-07 | 6.261E-06 | HSD17B1, CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP19A1 |
09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 9.186E-07 | 1.872E-05 | MMP1, SRC, MMP2, MMP9, EGFR |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.083E-05 | 1.766E-04 | FLT3, MET, HIF1A, EGFR, MTOR |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 3.766E-05 | 4.722E-04 | SRC, INSR, KDR, TEK, MET, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 5.983E-05 | 6.502E-04 | INSR, KDR, TEK, MET, EGFR, NFKB1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 4.553E-05 | 5.301E-04 | PIM1, CYP1B1, MMP9, MET, EGFR, NFKB1, MTOR, CDC25B |
09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 1.252E-05 | 1.855E-04 | FABP3, FABP4, FABP5, MMP1, PPARA |
09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 1.441E-05 | 1.957E-04 | SLCO1B1, CA2, SLCO1B3, NR1H4, SLC5A1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 1.193E-04 | 1.144E-03 | INSR, KDR, TEK, MET, EGFR, NFKB1, MTOR, IGF1R |
09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 1.363E-04 | 1.169E-03 | SMAD3, SRC, KDR, MET, EGFR, HSPA1A, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 1.107E-04 | 1.127E-03 | FLT3, PIM1, NFKB1, MTOR |
09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 1.350E-04 | 1.169E-03 | HPGD, FLT3, MMP9, MET, NFKB1, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 1.650E-04 | 1.344E-03 | THRB, SRC, ESR1, HIF1A, MTOR |
09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 1.739E-04 | 1.350E-03 | INSR, MTOR, HSPA1A, IGF1R |
09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.200E-04 | 1.630E-03 | SRC, MET, EGFR, NFKB1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 2.743E-04 | 1.863E-03 | SRC, ESR1, NFKB1, ESR2 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 8.773E-04 | 4.766E-03 | ALOX15, AKR1B1, ALOX12, CYP2C19, TYR, CYP19A1, HSD17B10, FUT7, AKR1B10, HSD17B1, HSD17B2, CYP1A2, CYP1A1, ALPL |
09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 6.154E-04 | 3.715E-03 | EGFR, NFKB1, MTOR, IGF1R |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 9.891E-04 | 5.201E-03 | SMAD3, MMP2, PIM1, NFKB1 |
09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 7.560E-04 | 4.249E-03 | INSR, NFKB1, MTOR, IGF1R |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 5.897E-04 | 3.697E-03 | TUBB3, SRC, CDK1, EGFR |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 4.511E-04 | 2.941E-03 | CYP1A2, CYP1A1, CYP1B1, CYP2C19 |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 1.313E-03 | 6.687E-03 | INSR, PPARA, NFKB1, MTOR |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 1.891E-03 | 9.065E-03 | SRC, KDR, MET, EGFR, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 1.866E-03 | 9.065E-03 | FABP4, INSR, TSHR |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 6.992E-04 | 4.071E-03 | CYP1A2, CYP1A1, CYP1B1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 2.677E-04 | 1.863E-03 | CYP1A2, ALOX15, CYP2C19 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | F10; F2; |
NA: NA | Edema | NA | CA2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
NA: NA | HIV infections | NA | AHR; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; MTOR; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; NPSR1; F2; |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; PIM1; MET; CDK1; IGF1R; KDR; CSNK2A1; NFKB1; FLT3; ACHE; HIF1A; TEK; MMP9; EGFR; SRC; MMP2; F2; CDC25B; MTOR; |
I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F10; F2; |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MTOR; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; MMP2; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; F10; MTOR; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Transplant rejection | D89.8, T86 | MTOR; |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; SLC5A2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; INSR; SLC5A4; SLC5A1; SLC5A2; FFAR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR; SLC5A4; |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | TEK; SRC; |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood forming organ disorders | D75.9 | F2; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; EGFR; |
I00-I99: Diseases of the circulatory system | Prophylaxis of deep vein thrombosis | I80-I82, I80.2 | F10; |
C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; FLT3; EGFR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | THRB; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; TEK; |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; SRC; |
C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; CYP19A1; MTOR; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood coagulation disorders | D65-D68 | F10; F2; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
I00-I99: Diseases of the circulatory system | Venous thrombosis | I80-I82 | F10; F2; |
I00-I99: Diseases of the circulatory system | Venous thromboembolism | I80-I82 | F10; F2; |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; MMP2; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; INSR; EGFR; MTOR; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2B; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; EGFR; MMP2; MTOR; |
I00-I99: Diseases of the circulatory system | Coagulation | I80-I82 | F10; F2; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; F2; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Wound healing | T14.0-T14.1 | THRB; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR; ALPL; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
NA: NA | Christmas disease | NA | F10; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypothyroidism | E03 | THRB; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hematology | D50-D77 | F10; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | F10; F2; |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | F10; EGFR; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; IGF1R; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; MTOR; |
NA: NA | Coronary artery restenosis | NA | MTOR; |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
E00-E89: Endocrine, nutritional and metabolic diseases | High cholesterol levels in blood | E78.0 | THRB; |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
I00-I99: Diseases of the circulatory system | Stroke in atrial fibrillation | I48, I61-I63 | F2; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; SLC5A2; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; MMP9; EGFR; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; SRC; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hemophilia | D66-D68 | F10; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; INSR; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Thrombocytopenia | D69.6, P61.0 | F2; |
I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | F10; F2; |
I00-I99: Diseases of the circulatory system | Thromboembolic disorders | I80-I82 | F10; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperthyroidism | E05 | THRB; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; INSR; THRB; |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; CYP19A1; |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; MMP2; |
I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | F10; |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK; MMP1; |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
NA: NA | Postmenopausal disorder | NA | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
NA: NA | Gonorrheal vaginitis | NA | ESR1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
NA: NA | GIST | NA | FLT3; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; AKR1B1; |
C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; CDK1; IGF1R; ACHE; INSR; MTOR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; INSR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | F10; |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | F2; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; F2; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; SRC; MTOR; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
C00-D49: Neoplasms | Sarcoma | C81-C86 | MTOR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; SRC; |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; EGFR; MMP2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
I00-I99: Diseases of the circulatory system | Deep vein thrombosis | I80-I82, I80.2 | F10; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; EGFR; AKR1B1; |
I00-I99: Diseases of the circulatory system | Heart arrhythmia | I47-I49 | F2; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
A00-B99: Certain infectious and parasitic diseases | Dutch elm disease | B81-B83 | MTOR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Organ rejection | D89.8, T86 | MTOR; |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; EGFR; SRC; |
C00-D49: Neoplasms | Breast cancer | C50 | ESR1; CDK1; IGF1R; KDR; FLT3; INSR; EGFR; CYP19A1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | INSR; AKR1B1; SLC5A4; SLC5A1; SLC5A2; FFAR1; |
I00-I99: Diseases of the circulatory system | Deep venous clots | I80.2 | F10; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
NA: NA | Haemophilia B | NA | F10; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR; FFAR1; |
C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | MTOR; |
NA: NA | Nonvalvular atrial fibrillation | NA | F2; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; EGFR; MTOR; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; MMP2; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | TOP2A; MET; AURKB; IGF1R; KDR; FLT3; HIF1A; TEK; MMP9; EGFR; SRC; MMP2; F2; MTOR; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; EGFR; TYR; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
NA: NA | Menopausal disorder | NA | ESR1; |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADRA2B; |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
C00-D49: Neoplasms | Advanced kidney cancer | C64 | MTOR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; MMP1; TYR; |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | F2; |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | F10; F2; |